Moderna (NASDAQ:MRNA) reported a massive full-year loss and revealed a significant regulatory setback in the U.S., as the Food and Drug Administration refused to review its experimental flu vaccine, complicating the biotech’s path to profitability.
West Pharmaceutical Services (NYSE:WST) shares gained momentum Thursday after the injectable-solution leader posted a fourth-quarter earnings beat and provided a bullish 2026 outlook, fueled by the explosive growth of GLP-1 "obesity" drugs and a massive jump in free cash flow.
Agios Pharmaceuticals (NASDAQ:AGIO) today released financial results and business updates for the fourth quarter and full year ended December 31, 2025, highlighting regulatory progress and commercial momentum in rare blood disorders.
Upstream Bio (NASDAQ:UPB) announced breakthrough results for its lead candidate, verekitug, in a mid-stage trial that could disrupt the multibillion-dollar biologics market for severe respiratory diseases.
Veru (NASDAQ:VERU) reported a significantly narrowed operating loss for the first fiscal quarter, as the biopharmaceutical firm pivots its resources toward a high-stakes clinical trial for its muscle-preserving obesity treatment.
Merck (NYSE:MRK) reached a historic milestone in oncology today as the FDA approved KEYTRUDA (pembrolizumab) and its new subcutaneous twin, KEYTRUDA QLEX, for the treatment of platinum-resistant ovarian cancer.
Agilent Technologies (NYSE:A) announced today that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx as the first and only companion diagnostic to identify first-line patients with epithelial ovarian cancer (EOC) eligible for Merck’s blockbuster immunotherapy, KEYTRUDA.
Tenet Healthcare (NYSE:THC) posted a sharp rise in fourth-quarter profitability, fueled by a surge in high-acuity surgical procedures and the strategic streamlining of its hospital portfolio.
Avantor (NYSE:AVTR) is betting on a structural overhaul to break a cycle of underperformance, unveiling its "Revival" transformation program alongside fourth-quarter results that showed persistent revenue pressure.
Humana (NYSE:HUM) issued a sobering outlook for 2026, projecting that a significant drop in government bonus payments will weigh on its bottom line even as the insurer sees a massive rebound in customer acquisition.
Madrigal Pharmaceuticals (NASDAQ:MDGL) is doubling down on its dominance of the liver-disease market, announcing an expansive partnership with Ribo to develop next-generation gene-silencing therapies.
IRADIMED (NASDAQ:IRMD), a leader in MRI-compatible medical devices, reported record financial results for the fourth quarter and full year ended December 31, 2025.
